LEAH Labs GTM brain

LEAH Labs develops investigational CAR-T cell therapies for dogs with lymphoma through veterinary clinical trial partners.

category

Veterinary cell therapy

market profile

  • text: The current focus is a clinical trial in canine B-cell lymphoma; commercial availability and future pricing are not established.
  • text: Standard multi-agent chemotherapy involves repeated veterinary visits and relapse remains common, according to the Minnesota trial description.

personas

  • title: Veterinary oncologist and clinical trial investigator
    pains:
    • Dogs with B-cell lymphoma may relapse after chemotherapy.
    • New treatments require safety evidence, eligible patients and close monitoring.
  • title: Dog owner navigating a lymphoma diagnosis
    pains:
    • Treatment decisions carry emotional, financial and travel burdens.
    • Standard chemotherapy involves repeated appointments and may not provide durable remission.
  • title: Biopharma translational research leader
    pains:
    • Human cancer therapy development is slow and early models may not reflect naturally occurring disease.
    • Clinical partners are needed to test translational hypotheses.

icp

  • text: US veterinary teaching hospitals and oncology practices able to assess and refer eligible dogs with B-cell lymphoma.
  • text: Families able to travel to an active study site and whose dogs satisfy trial eligibility; not all dogs qualify.

message pillars

  • text: Develop therapies for pets with potential translational relevance.
  • text: Engineer immune cells to fight cancer.
  • text: Remove the treatment cost barrier for enrolled trial families.

objections

  • objection: Is this a proven or commercially approved cure?
    response: This is an investigational clinical trial; discuss evidence, risks and eligibility with the veterinary trial team.
  • objection: Can my dog participate without travel?
    response: The company lists three partner institutions; contact the study team about eligibility and required visits.
  • objection: Can our practice afford to refer clients?
    response: The company says treatment is free for enrolled families; clarify travel and non-study expenses with the study site.

competitors

  • name: Elanco
    why: Commercial canine lymphoma treatment is an alternative to investigational cell therapy.
  • name: VetDC
    why: Developed a canine B-cell lymphoma chemotherapy licensed to Elanco.

influencers

  • name: Alex M. Abel
    url: https://www.linkedin.com/posts/alex-abel_clinical-trial-car-t-cell-therapy-for-dogs-activity-6971533102980427776-TU8M
    why: LEAH scientific leader sharing the clinical trial journey.

keywords

  • dog B cell lymphoma clinical trial
  • canine CAR T therapy
  • veterinary lymphoma treatment
  • dog cancer immunotherapy
  • canine oncology trial
  • lymphoma chemotherapy alternatives dogs

voice

  • hopeful and mission-led
  • science-forward with pet-family language

signals

  • text: A veterinary oncology center is seeking eligible canine lymphoma trials or research partnerships.
  • text: A dog is diagnosed with B-cell lymphoma near a participating trial center and the owner is exploring options.

pricing

model: unknown

motion

sales_led

channels

  • veterinary hospital partnerships
  • clinical trial referrals
  • LinkedIn
  • research press

confidence

medium

Founders

  • name: Wesley Wierson
    title: Founder
    role: Founder
    bio: I am a scientist and entrepreneur applying my expertise in gene editing towards solving consumer level problems in society, first focused on building curative cancer therapies for pets, and eventually their owners. Through my time at LEAH Labs, I've also found a passion for biotech business model innovation through regulatory arbitrage - e.g. CAR-T in pets is regulated by USDA, not FDA, thus we can get to market 2-3x faster and for 500x less capital than human CAR-T

Back to YC companies